Cargando…

Tapentadol, the new kid on the block in India: Is it time to worry?

BACKGROUND AND OBJECTIVES: Large-scale prospective case series of tapentadol abuse or dependence in India is not available. Hence, we aimed to study the prevalence and profile of tapentadol users in a treatment-seeking population. MATERIALS AND METHODS: The study had prospective and retrospective ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Basu, Debasish, Mahintamini, Tathagata, Ghosh, Abhishek, Roub, Fazle, Subodh, B. N., Mattoo, S. K., Avasthi, Ajit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052882/
https://www.ncbi.nlm.nih.gov/pubmed/33896976
http://dx.doi.org/10.4103/psychiatry.IndianJPsychiatry_332_20
_version_ 1783680013537640448
author Basu, Debasish
Mahintamini, Tathagata
Ghosh, Abhishek
Roub, Fazle
Subodh, B. N.
Mattoo, S. K.
Avasthi, Ajit
author_facet Basu, Debasish
Mahintamini, Tathagata
Ghosh, Abhishek
Roub, Fazle
Subodh, B. N.
Mattoo, S. K.
Avasthi, Ajit
author_sort Basu, Debasish
collection PubMed
description BACKGROUND AND OBJECTIVES: Large-scale prospective case series of tapentadol abuse or dependence in India is not available. Hence, we aimed to study the prevalence and profile of tapentadol users in a treatment-seeking population. MATERIALS AND METHODS: The study had prospective and retrospective arms. We collected 8-month prospective data by face-to-face interviews (n = 70) and 8-year retrospective data from case notes (n = 26) with either tapentadol misuse/abuse or dependence in patients attending a de-addiction center. RESULTS: The prevalence of tapentadol abuse or dependence was 25% among the pharmaceutical opioid users. Concurrent use of other opioids was seen in >80% of participants of both the arms. Major sources of tapentadol were chemists (without a prescription) (53%) and doctors (prescriptions) (40%). Patients in the tapentadol dependence group had a significantly higher dose, duration, and pharmaceutical opioid use. CONCLUSION: India needs awareness promotion, training, availability restriction, and provision of treatment for tapentadol abuse or dependence.
format Online
Article
Text
id pubmed-8052882
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-80528822021-04-23 Tapentadol, the new kid on the block in India: Is it time to worry? Basu, Debasish Mahintamini, Tathagata Ghosh, Abhishek Roub, Fazle Subodh, B. N. Mattoo, S. K. Avasthi, Ajit Indian J Psychiatry Original Article BACKGROUND AND OBJECTIVES: Large-scale prospective case series of tapentadol abuse or dependence in India is not available. Hence, we aimed to study the prevalence and profile of tapentadol users in a treatment-seeking population. MATERIALS AND METHODS: The study had prospective and retrospective arms. We collected 8-month prospective data by face-to-face interviews (n = 70) and 8-year retrospective data from case notes (n = 26) with either tapentadol misuse/abuse or dependence in patients attending a de-addiction center. RESULTS: The prevalence of tapentadol abuse or dependence was 25% among the pharmaceutical opioid users. Concurrent use of other opioids was seen in >80% of participants of both the arms. Major sources of tapentadol were chemists (without a prescription) (53%) and doctors (prescriptions) (40%). Patients in the tapentadol dependence group had a significantly higher dose, duration, and pharmaceutical opioid use. CONCLUSION: India needs awareness promotion, training, availability restriction, and provision of treatment for tapentadol abuse or dependence. Wolters Kluwer - Medknow 2020 2020-12-12 /pmc/articles/PMC8052882/ /pubmed/33896976 http://dx.doi.org/10.4103/psychiatry.IndianJPsychiatry_332_20 Text en Copyright: © 2020 Indian Journal of Psychiatry https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Basu, Debasish
Mahintamini, Tathagata
Ghosh, Abhishek
Roub, Fazle
Subodh, B. N.
Mattoo, S. K.
Avasthi, Ajit
Tapentadol, the new kid on the block in India: Is it time to worry?
title Tapentadol, the new kid on the block in India: Is it time to worry?
title_full Tapentadol, the new kid on the block in India: Is it time to worry?
title_fullStr Tapentadol, the new kid on the block in India: Is it time to worry?
title_full_unstemmed Tapentadol, the new kid on the block in India: Is it time to worry?
title_short Tapentadol, the new kid on the block in India: Is it time to worry?
title_sort tapentadol, the new kid on the block in india: is it time to worry?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052882/
https://www.ncbi.nlm.nih.gov/pubmed/33896976
http://dx.doi.org/10.4103/psychiatry.IndianJPsychiatry_332_20
work_keys_str_mv AT basudebasish tapentadolthenewkidontheblockinindiaisittimetoworry
AT mahintaminitathagata tapentadolthenewkidontheblockinindiaisittimetoworry
AT ghoshabhishek tapentadolthenewkidontheblockinindiaisittimetoworry
AT roubfazle tapentadolthenewkidontheblockinindiaisittimetoworry
AT subodhbn tapentadolthenewkidontheblockinindiaisittimetoworry
AT mattoosk tapentadolthenewkidontheblockinindiaisittimetoworry
AT avasthiajit tapentadolthenewkidontheblockinindiaisittimetoworry